1 / 20

Figure S1

Figure S1. A. *. *. *. B. *. *. *. *. *. *. *. *. *. *. Figure S2. A. Fold Increase. OxPhos Genes. B. Figure S3. A. ECAR ( mpH /min) or OCR ( pmol /min). C. SEL-Resistant. SEL-Sensitive. Relative Luciferase Activity (ATP). B. SEL-Sensitive. SEL-Resistant.

hasana
Download Presentation

Figure S1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure S1 A. * * * B. * * * * * * * * * *

  2. Figure S2 A. Fold Increase OxPhos Genes B.

  3. Figure S3 A. ECAR (mpH/min) or OCR (pmol/min) C. SEL-Resistant SEL-Sensitive Relative Luciferase Activity (ATP) B. SEL-Sensitive SEL-Resistant Concentration (mmol/L) SEL-Sensitive SEL-Resistant

  4. Figure S4 CI >1.0 CI <1.0 P < 0.0001

  5. Figure S5 A. Dead Cells (%) B. C. PGC1α [Treatment : Mock] OCR (pmoles/min)

  6. Figure S6 Tumor Suppression mTOR1/2 Activity A. 1 2 Proliferation MAPK Activity RTK Activation B. 1 2

  7. Figure S6 C. P-MAPK (T202_Y204) P-S6 (S235_S236) Relative Protein Levels Relative Protein Levels SKMEL5 D24 D29 WM1799 UCSD354 MEL624 SKMEL5 D24 D29 WM1799 UCSD354 MEL624 P-AKT (T308) Cl. Caspase 7 Relative Protein Levels Relative Protein Levels SKMEL5 D24 D29 WM1799 UCSD354 MEL624 SKMEL5 D24 D29 WM1799 UCSD354 MEL624

  8. Figure S6 D. Tumor Suppression Apoptosis Proliferation AKT Activity RTK Activation MAPK & mTOR1/2 Activity

  9. Figure S7 B. A. R2=0.32 p=0.03 R2=0.54 p=0.002

  10. Figure S7 D. C. WM3854 MEL624 mRNA [Treatment : Mock] mRNA [Treatment : Mock] WM3854 E. RLU

  11. Figure S8 A. AZD8055 SEL+8055 Mock SEL DAPI MITF Merge

  12. Figure S8 C. MEL624 MEL624 B. RLU RLU * * * * * *

  13. Figure S8 D. RAPTOR+RICTOR RAPOR+RICTOR RAPTOR RAPTOR RICTOR RICTOR mTOR PGC1a mTOR PGC1a MITF MITF Risc Risc PGC1α PGC1α MITF MITF mTOR mTOR Raptor Raptor Rictor Rictor P-S6(S235/236) P-S6(S235/236) S6 S6 P-4EBP1(S65) P-4EBP1(S65) P-AKT(S473) P-AKT(S473) AKT AKT MEL624 WM3854

  14. Figure S9 A. C. SEL+AZD2014 SEL+AZD8055 AZD2014 AZD8055 Mock SEL PGC1α Relative Intensity MITF GAPDH B. Mock 2014 8055 Effect of mTORC1/2 Inhibition

  15. Figure S10 F O B. A. OCR (pmol/min/25,000 cells) % Inhibition % Inhibition SEL (mM) Time (min) SEL (mM) C.

  16. Figure S10 E. P-S6 D. Parental Clone R1 Clone R2 P-MAPK Clone R1 Parental Clone R2

  17. Figure S11 B. C. A. A375 A375-R1 A375-R2 Inhibition (%) Concentration (mM) Concentration (mM) Concentration (mM) E. D. F. WM35 WM35-R1 WM35-R2 Inhibition (%) Concentration (mM) Concentration (mM) Concentration (mM)

  18. Figure S11 G. Sel+8055 Mock Sel AZD8055 A375 A375-R1

  19. Figure S12 A. mRNA [Prog : Pre] Patient samples

  20. Figure S12 B. 166 Lung Cancers 59 Melanomas 59 Melanomas Relative PGC1a Expression 172 Hematopoietic & Lymphoid Cancers Cancers by Tissue Type

More Related